For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
24
views
34
references
 Top references
cited by
127
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      966
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Atopic dermatitis is a chronic inflammatory skin disease that may require systemic therapy. Ciclosporin A (CsA) is a widely used, potent immunosuppressant but it is not effective in all patients with atopic dermatitis, and side-effects limit its use. Dupilumab, a fully human anti-interleukin 4 receptor-alpha monoclonal antibody, inhibits signaling of IL-4 and IL-13, key drivers of Type 2/Th2-mediated inflammation, and is approved in the U.S.A. and the European Union for the treatment of inadequately-controlled moderate-to-severe atopic dermatitis in adults.

          Related collections

          Most cited references34

          • Record: found
          • Abstract: found
          • Article: not found

          Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.

          Lawrence F. Eichenfield, Wynnis L. Tom, Sarah L Chamlin … (2014)
          Atopic dermatitis (AD) is a chronic, pruritic, inflammatory dermatosis that affects up to 25% of children and 2% to 3% of adults. This guideline addresses important clinical questions that arise in the management and care of AD, providing updated and expanded recommendations based on the available evidence. In this first of 4 sections, methods for the diagnosis and monitoring of disease, outcomes measures for assessment, and common clinical associations that affect patients with AD are discussed. Known risk factors for the development of disease are also reviewed. Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
          Article 0 comments Cited 306 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.

            Sally Wenzel, Mario Castro, Jonathan Corren … (2016)
            Dupilumab, a fully human anti-interleukin-4 receptor α monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation. Adults with uncontrolled persistent asthma who are receiving medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist require additional treatment options as add-on therapy. We aimed to assess the efficacy and safety of dupilumab as add-on therapy in patients with uncontrolled persistent asthma on medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist, irrespective of baseline eosinophil count.
            Article 0 comments Cited 300 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Atopic dermatitis: a disease of altered skin barrier and immune dysregulation.

              Mark Boguniewicz, Donald Y M Leung (2011)
              Atopic dermatitis (AD) is an important chronic or relapsing inflammatory skin disease that often precedes asthma and allergic disorders. New insights into the genetics and pathophysiology of AD point to an important role of structural abnormalities in the epidermis as well as immune dysregulation not only for this skin disease but also for the development of asthma and allergies. Patients with AD have a unique predisposition to colonization or infection by microbial organisms, most notably Staphylococcus aureus and herpes simplex virus. Measures directed at healing and protecting the skin barrier and addressing the immune dysregulation are essential in the treatment of patients with AD, and early intervention may improve outcomes for both the skin disease as well as other target organs. © 2011 John Wiley & Sons A/S.
              Article 0 comments Cited 292 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Title: British Journal of Dermatology
                Abbreviated Title: Br J Dermatol
                Publisher: Wiley
                ISSN: 00070963
                Publication date Created: May 2018
                Publication date (Print): May 2018
                Publication date (Electronic): March 25 2018
                Volume: 178
                Issue: 5
                Pages: 1083-1101
                Affiliations
                [1 ]University Medical Center Utrecht; Utrecht the Netherlands
                [2 ]University of Lübeck; Lübeck Germany
                [3 ]St. John's Institute of Dermatology; London U.K.
                [4 ]Dermatologikum and TFS Research Institute; Hamburg Germany
                [5 ]Sheffield Dermatology Research; The University of Sheffield; Sheffield U.K.
                [6 ]Regeneron Pharmaceuticals, Inc.; Tarrytown NY U.S.A.
                [7 ]Regeneron Pharmaceuticals, Inc.; Basking Ridge NJ U.S.A.
                [8 ]Sanofi; Chilly-Mazarin France
                [9 ]Sanofi; Cambridge MA U.S.A.
                [10 ]Sanofi; Bridgewater NJ U.S.A.
                Article
                DOI: 10.1111/bjd.16156
                PubMed ID: 29193016
                SO-VID: 7bec5005-4b31-4bc6-aedb-442c5cd4b4af
                Copyright © © 2018
                License:

                http://doi.wiley.com/10.1002/tdm_license_1.1

                http://creativecommons.org/licenses/by-nc-nd/4.0/

                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content966

                See all similar

                Cited by150

                See all cited by

                Most referenced authors732

                See all reference authors